Semaglutide: difference between revisions
Diff·revision 22 → 23·20:44, 1 May 2025
Difference between revision 22 and revision 23 of Semaglutide. 6 lines changed; the page grew by 481 bytes.
| Revision 22 — 03:34, 11 Apr 2025 ArchiveBot (talk) bot: expand DOI to full citation 8,079 bytes ±0 | Revision 23 — 20:44, 1 May 2025 SecretagogueSol (talk) reorder the analogues chronologically rather than alphabetically 8,560 bytes +481 | ||
|---|---|---|---|
| 63 | Cholelithiasis and cholecystitis occur more often than on placebo, a finding consistent across rapid weight loss by other means and probably not specific to the drug. Acute pancreatitis is rare and its causal relationship remains debated. The label carries a contraindication in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, derived from rodent C-cell tumour findings whose human relevance is unestablished.{{r|lincoff2023}} | 63 | Cholelithiasis and cholecystitis occur more often than on placebo, a finding consistent across rapid weight loss by other means and probably not specific to the drug. Acute pancreatitis is rare and its causal relationship remains debated. The label carries a contraindication in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, derived from rodent C-cell tumour findings whose human relevance is unestablished.{{r|lincoff2023}} |
| 64 | 64 | ||
| + | 65 | Delayed gastric emptying has prompted revised preoperative fasting guidance; see [[Aspiration risk under anaesthesia]]. A fuller account of class-wide effects is at [[Adverse effects of GLP-1 receptor agonists]]. | |
| + | 66 | ||
| 65 | == References == | 67 | == References == |
| 66 | {{reflist}} | 68 | {{reflist}} |
| ⋮ | ⋮ | ||
| 70 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | 72 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> |
| 71 | 73 | ||
| + | 74 | == Further reading == | |
| + | 75 | * Mahapatra MK, Karuppasamy M, Sahoo BM. "Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits." ''Reviews in Endocrine and Metabolic Disorders'' 23(3):521–539 (2022). | |
| + | 76 | ||
| 72 | == See also == | 77 | == See also == |
| 73 | * [[GLP-1 receptor agonist]] | 78 | * [[GLP-1 receptor agonist]] |
| ⋮ | ⋮ | ||
| 77 | * [[STEP trial programme]] | 82 | * [[STEP trial programme]] |
| 78 | * [[SELECT trial]] | 83 | * [[SELECT trial]] |
| + | 84 | * [[Albumin binding half-life extension]] | |
| 79 | 85 | ||
| 80 | {{DEFAULTSORT:Semaglutide}} | 86 | {{DEFAULTSORT:Semaglutide}} |